Compare Bristol-Myers Squibb Co (BMY) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Mondaycom Ltd — how do they compare? Bristol-Myers Squibb Co trades at $58.68 (market cap $116.30B), while Mondaycom Ltd trades at $83.71 (market cap $3.51B). The key difference: Bristol-Myers Squibb Co is far larger — about 33.1× Mondaycom Ltd's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| BMY | MNDY | |
|---|---|---|
Market Cap | $116.30B | $3.51B |
Sector | Health | Technology |
52-Week High | $62.37 | $292.24 |
52-Week Low | $42.60 | $58.81 |
Enterprise Value | $152.24B | $2.47B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Monday.com (MNDY) trades at $86.84, up 5.3% in the past 24 hours, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings expectations, with Q1 2026 EPS of $1.15 surpassing the $0.96 estimate. Revenue grew to $1.23 billion in 2025, though net income remained flat at $119 million year-over-year. Recent news highlights investor attention amid a 51% decline in the first half of 2026, with some viewing the dip as a buying opportunity due to solid fundamentals.
The outlook for MNDY is positive, driven by robust revenue growth, high gross margins of 89.05%, and a unanimous analyst buy consensus with a $115.50 price target. Key risks include elevated valuation multiples, competitive pressures in the SaaS space, and volatility from AI disruption concerns. Investors should weigh the company's execution against its premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
